



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449A/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

<i>Complete if Known</i>	
Application Number	10/715,547
Filing Date	November 19, 2003
First Named Inventor	Alexander LEVITZKI et al
Art Unit	1624
Examiner Name	TRUONG, TAMTHOM NGO

Sheet 1 of 4 Attorney Docket Number 27148

## U.S. PATENT DOCUMENTS

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Documents	Publication Date DD-MMM-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	7	EP 1228072	07-Aug-2002	Levitzki et al.		
	8	PCT WO 01/34607	17-May-2001	Levitzki et al.		
	9	PCT WO 96/29331	26-Sep-1996	Himmelsbach et al.		
	10	PCT WO 99/07701	18-Feb-1999	Tang et al.		
	11	PCT WO 99/28304	10-Jun-1999	Levitzki et al.		
	12	PCT WO 99/46264	16-Sep-1999	Karabelas et al.		
Examiner				Date		

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> Enter Office that issued the document, by the two-letter code (WI = Standard U.S.).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	Of	4	Attorney Docket Number	27148
-------	---	----	---	------------------------	-------

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	13	Akbasak et al. "Oncogenes: Cause or Consequence in the Development of Glial Tumors", J. Neurological Sciences, 111: 119-133, 1992.	
	14	Bilder et al. "Tyrophostins Inhibit PDGF-Induced DNA Synthesis and Associated Early Events in Smooth Muscle Cells", Am. J. Physiol., 260: C721-C730, 1991.	
	15	Bryckaert et al. "Inhibition of Platelet-Derived Growth Factor-Induced Mitogenesis and Tyrosine Kinase Activity in Cultured Bone Marrow Fibroblasts by Tyrophostins", Exp. Cell Res., 199: 255-261, 1992.	
	16	Claesson-Welsh "cDNA Cloning and Expression of the Human A-Type Platelet-Derived Growth Factor (PDGF) Receptor Establishes Structural Similarity to the B-Type PDGF Receptor", Proc. Natl. Acad. Sci. USA, 86: 4917-4921, 1989.	
	17	Demirayak et al. "Synthesis of Some 6, 7-Distributed Imidazo '4,5-g' Quinoxaline Derivatives as Possible Antimicrobials", Acta Pharmaceutica Turcia, 40(4): 193-196, 1998. Tab.1, 2.	
	18	Dickson et al. "Tyrosine Kinase Receptor-Nuclear Protooncogene Interactions in Breast Cancer", Cancer Treatment Res., 61: 249-273, 1992.	
	19	Donners et al. "Inflammation and Restenosis: Implication for Therapy", Trends in Molecular Medicine, Annals of Medicine, 35: 523-531, 2003.	
	20	Doolittle et al. "Simian Sarcoma Virus Onc Gene, V-Sis, Is Derivated From the Gene (or Genes) Encoding A Platelet-Derived Growth Factor", Science, 221: 275-277, 1983.	
	21	Engström et al. "Identification of A Peptide Antagonist for Platelet-Derived Growth Factor", J. Biological Chemistry, 267(23): 16581-16587, 1992.	
	22	Eriksson et al. "PDGF α- and β-Receptors Activate Unique and Common Signal Transduction Pathways", The EMBO Journal, 11(2): 543-550, 1992.	
	23	Escobedo et al. "Role of Tyrosine Kinase and Membrane-Spanning Domains in Signal Transduction by the Platelet-Derived Growth Factor Receptor", Molecular and Cellular Biology, 8(12): 5126-5131, 1988.	
	24	Fridman et al. "Derivatives of Imidazobenzothiadiazole, Imidazo-Benzoselenodiazole, Imidazobenzotriazole and Imidazoquinoxaline", Zhurnal Obshchey Kimii, UA, 32(9): 2829-2838, 1962.	
	25	Fry et al. "Recent Advances in Tyrosine Inhibitors", Annual Reports in Medicinal Chemistry, 31: 151-160, 1996.	
Examiner Signature		Date Considered	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

*Complete if Known*

Application Number	10/715,547
Filing Date	November 19, 2003
First Named Inventor	Alexander LEVITZKI et al
Art Unit	1624
Examiner Name	TRUONG, TAMTHOM NGO

Sheet 3 Of 4 Attorney Docket Number 27148

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	26	Gershlick et al. "Dealing With In-Stent Restenosis", Heart, 79(4): 319-323, 1998.	
	27	Gesualdo et al. "Platelet-Derived Growth Factor and Proliferative Glomerulonephritis", Kidney International, 43(Suppl.39): S86-S89, 1993.	
	28	Golomb et al. "Controlled Delivery of a Tyrophostin Inhibits Intimal Hyperplasia in a Rat Carotid Artery Injury Model", Artherosclerosis, 125: 171-182, 1996.	
	29	Hawley "Gen-Flo Latices", The Condensed Chemical Dictionary, 9th Ed., P.410, 1977.	
	30	Heldin "Structural and Functional Studies on Platelet-Derived Growth Factor", The EMBO J., 11(12): 4251-4259, 1992.	
	31	Heldin et al. "Platelet-Derived Growth Factor and Autocrine Mechanisms of Oncogenic Processes", CRC Crit. Rev. Oncog., 2: 109-124, 1991.	
	32	Korc et al. "Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer Is Associated With Concomitant Increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha", J. Clin. Invest., 90: 1352-1360, 1992.	
	33	Kovalenko et al. "Phosphorylation Site-Specific Inhibition of Platelet-Derived Growth Factor β-Receptor Autophosphorylation by the Receptor Blocking Tryphostin AG 1296", Biochemistry, 36: 6260-6269.	
	34	Kovalenko et al. "Selective Platelet-Derived Growth Factor Receptor Kinase Blockers Reverse Sis-Transformation", Cancer Research, 54: 6106-6114, 1994.	
	35	Leonard et al. "Linear Benzoadenine, A Streched-Out Analog of Adenine", J. Org. Chem., 40(3): 356-363, 1975	
	36	Levitzki "Tyrophostins: Tyrosine Kinase Blockers as Novel Antiproliferative Agents and Dissectors of Signal Transduction", FASEB J., 6: 3275-3282, 1992.	
	37	Matsui et al. "Isolation of A Novel Receptor cDNA Establishes the Existence of Two PDGF Receptor Genes", Science, 243: 800-804, 1989.	
	38	Öberg et al. "Expression of Protein Tyrosine Kinases in Islet Cells: Possible Role of the Flk-1 Receptor for β-Cell Maturation From Duct Cells", Growth Factors, 10: 115-126, 1994.	
Examiner Signature		Date Considered	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional).

2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

6 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

*Complete if Known*

Application Number	10/715,547
Filing Date	November 19, 2003
First Named Inventor	Alexander LEVITZKI et al
Art Unit	1624
Examiner Name	TRUONG, TAMTHOM NGO

Sheet 4 Of 4 Attorney Docket Number 27148

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	39	Ross "Mechanism of Atherosclerosis - A Review", Adv. Nephrol., 19: 79-86, 1990.	
	40	Ross "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s", Nature, 362: 801-809, 1993.	
	41	Ross et al. "Platelet-Derived Growth Factors", The Lancet, P.1179-1182, 1989.	
	42	Rubin et al. "Expression of Platelet-Derived Growth Factor Receptors Is Induced on Connective Tissue Cells During Chronic Synovial Inflammation", Scan. J. Immunol., 27: 285-294, 1998.	
	43	Shamah et al. "Dominant-Negative Mutants of Platelet-Derived Growth Factor Revert the Transformed Phenotype of Human Astrocytoma Cells", Molecular and Cellular Biology, 13(12): 7203-7212, 1993.	
	44	Shaw et al. "Pathogenesis of Pulmonary Fibrosis in Interstitial Lung Disease", Am. Rev. Respir. Dis., 143: 167-173, 1991.	
	45	Sheldrick "Crystallographic Algorithms for Mini and Maxi Computers", Crystallographic Computing, Oxford University Press, GB, 3: 175-189, 1985.	
	46	Sirois et al. "Antisense Oligonucleotide Inhibition of PDGF-β Subunit Expression Directs Suppression of Intimal Thickening", Circulation, 95: 669-676, 1977.	
	47	Ueno et al. "Inhibition of PDGF β Receptor Signal Transduction by Coexpression of A Truncated Receptor", Science, 252: 844-848, 1991.	
	48	Vassbotn et al. "Reversion of Autocrine Transformation by A Dominant Negative Platelet-Derived Growth Factor Mutant", Molecular and Cellular Biology, 13(7): 4066-4076, 1993.	
	49	Waterfield et al. "Platelet-Derived Growth Factor Is Structurally Related to the Putative Transforming Protein P28sis of Simian Sarcoma Virus", Nature, 304: 35-39, 1983.	
	50	Westerman et al. "B-Type Receptor for A Platelet-Derived Growth Factor Mediates A Chemotactic Response by Means of Ligand-Induced Activation of the Receptor Protein-Tyrosine Kinase", Proc. Natl. Acad. Sci. USA, 87: 128-132, 1990.	
	51	Yarden et al. "Structure of the Receptor for Platelet-Derived Growth Factor Helps Define A Family of Closely Related Growth Factor Receptors", Nature, 323: 226-232, 1986.	
Examiner Signature		Date Considered	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

6 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450